Join
Live feed
·
PRReleasevia Quantisnow
Arbutus Biopharma Corporation logo

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

ByQuantisnow·Wall Street's wire, on your screen.
ABUS· Arbutus Biopharma Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABUS (Arbutus Biopharma Corporation) and more on Quantisnow.